TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01171118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: The administration of nasal cannula-administered oxygen at a flow rate of 2 liters/minute is commonly performed during clinical sedation practice. Thus, this experiment employed its use to compare respiratory effects of oxygen versus room air.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: The administration of nasal cannula-administered oxygen at a flow rate of 2 liters/minute is commonly performed during clinical sedation practice. Thus, this experiment employed its use to compare respiratory effects of oxygen versus room air.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
Study: NCT01681836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15Nitrogen(15N)-labeled sodium nitrate
Description: 15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
Study: NCT01519336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: 100 mg q12h
Study: NCT02119923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: The WM consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. The Number-letter task trains the ability to shift between task relevant stimuli. Participants need to shift between four categories. In the Updating task participants receive a set of three words in which they have to compare the two consecutive words on emotional valence (positive or negative) to train their updating skills. Participants executed the training three times a week during four weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo training
Description: Both the WM and the placebo training consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. To prevent training WM the placebo training was a simplified version of the Number-letter task in which shifting was not required. In the Updating task the placebo group only had to count the number of positive or negative words. Participants executed the training three times a week during four weeks.
Study: NCT01906892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group drumming (participatory)
Description: Active participation in group drumming workshops

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group drumming (participatory)
Description: Active participation in group drumming workshops

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group drumming (participatory)
Description: Active participation in group drumming workshops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group drumming (participatory)
Description: Active participation in group drumming workshops

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group drumming (participatory)
Description: Active participation in group drumming workshops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group drumming (participatory)
Description: Active participation in group drumming workshops
Study: NCT01519336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg q12h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: darunavir
Description: 600 mg q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: 600 mg q12h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: 100 mg q12h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ritonavir
Description: 100 mg q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg q12h
Study: NCT02387450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 100 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same presentation as the active drug
Study: NCT02111707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal indomethacin 100mg one time before or after ERCP
Description: Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
Study: NCT03809052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: Hard capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: Hard capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: Hard capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Hard capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Hard capsules for oral use
Study: NCT00923247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vandetanib
Description: This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
Study: NCT02691468

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC DLT
Description: PVC DLT is type of double lumen tube that is composed of PVC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: silicon DLT
Description: silicon DLT is type of double lumen tube that is composed of silicon
Study: NCT01906892

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group drumming (live)
Description: Listening to live performances of group drumming
Study: NCT00854061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-Pred
Description: sterile ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred Forte
Description: sterile ophthalmic solution
Study: NCT01776372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medela Thopaz Thoracic Drainage System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrium Express Dry Seal Chest Drain
Study: NCT02578095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK5211
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK5211
Description: Capsule
Study: NCT01906892

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group drumming (recorded)
Description: Listening to recorded performances of group drumming

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group drumming (recorded)
Description: Listening to recorded performances of group drumming

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparative activity
Description: Taking part in a literary-based activity
Study: NCT02578095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK5211
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT00320190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.
Study: NCT01906892

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparative activity
Description: Taking part in a literary-based activity
Study: NCT01016886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perindopril OR bisoprolol OR placebo
Description: perindopril- oral daily titrated does from 2mg up to 8mg~bisoprolol- oral daily titrated dose from 2.5mg up to 10mg
Study: NCT03011138

Intervention type: PROCEDURE
Intervention: Gait velocity
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.

Intervention type: PROCEDURE
Intervention: Gait velocity
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.

Intervention type: PROCEDURE
Intervention: Gait velocity
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.

Intervention type: PROCEDURE
Intervention: Gait velocity
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.

Intervention type: PROCEDURE
Intervention: Gait velocity
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.

Intervention type: PROCEDURE
Intervention: Gait velocity
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.
Study: NCT00320190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Dasatinib tablets administered orally at a dose of 100 mg once daily.
Study: NCT03011138

Intervention type: PROCEDURE
Intervention: Gait velocity
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.
Study: NCT00935610

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Immunocal
Description: 20 grams per day of Immunocal for 135 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immunocal
Description: 20 grams per day of Immunocal for 135 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Casein
Description: 20 grams per day for 135 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein
Description: 20 grams per day for 135 days
Study: NCT03560648

Intervention type: DEVICE
Group type: OTHER
Intervention: High definition surface electromyography combined with accelerometer
Description: HD-sEMG and accelerometer data will be collected by Mobita 32® (TMSi) device.

Intervention type: DEVICE
Group type: OTHER
Intervention: High definition surface electromyography combined with accelerometer
Description: HD-sEMG and accelerometer data will be collected by Mobita 32® (TMSi) device.
Study: NCT05104190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization of teeth during debonding using fingure pressure and elastic wafer
Description: To control pain during debonding in one group , teeth were stabilized with finger pressure with cotton between finger and teeth and then debonding using open mouth technique was done. In second group teeth were stabilized using a plastic wafer between maxillary and mandibular teeth and then debonding was done using closed mouth technique. In order to reduce biasness, all of the patients were debonded with same plier and with wires still ligated to brackets. With the help of VAS, pain score was measured after debonding. A single operator performed complete procedure of debonding and pain recording.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization of teeth during debonding using fingure pressure and elastic wafer
Description: To control pain during debonding in one group , teeth were stabilized with finger pressure with cotton between finger and teeth and then debonding using open mouth technique was done. In second group teeth were stabilized using a plastic wafer between maxillary and mandibular teeth and then debonding was done using closed mouth technique. In order to reduce biasness, all of the patients were debonded with same plier and with wires still ligated to brackets. With the help of VAS, pain score was measured after debonding. A single operator performed complete procedure of debonding and pain recording.
Study: NCT04084093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surfactant Gel
Description: This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.
Study: NCT04186351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Encounter notification service
Description: The caring support and services provided by SCHSA will consist of multiple components, including standard call \& care center support, medical appointment reminder, assistance to reschedule appointment, follow-up calls with either nurse or health workers to monitor health situation of service recipients, assessing needs of service recipient for elderly home care and/or rehabilitation services, providing elderly home care and/or rehabilitation services based on assessment, assessing needs of service recipient for emotional and community support, providing additional emotional support via either social calls by volunteers or counseling by social workers, and making referrals for community support services.
Study: NCT04435535

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PEP
Description: Positive expiratory pressure 10 cmH2O 15 min
Study: NCT02051400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the McGrath® MAC video laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the McGrath® MAC video laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the McGrath® MAC video laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the GlidesScope® Ranger video laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the GlidesScope® Ranger video laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the GlidesScope® Ranger video laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Macintosh laryngoscope
Study: NCT00987727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)
Description: One drop in each eye three to six times daily, as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium hyaluronate 0.18% (VISMED® Multi)
Description: One drop in each eye three to six times daily, as needed
Study: NCT02966236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT03086408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: active nasal oxygen delivery system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube or Supraglottic airway
Description: Plastic devices for mechanical ventilation
Study: NCT03171584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine
Description: oral antifungal drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine
Description: oral antifungal drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine
Description: oral antifungal drugs
Study: NCT01918605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diluted spacer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-diluted spacer
Study: NCT01377909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin
Description: daily statin orally for 48 weeks
Study: NCT01084291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Vaccine for DEN1
Description: Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Subcutaneous injection of placebo
Study: NCT00923247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vandetanib
Description: This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
Study: NCT02071914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P27
Description: Influenza A treatment drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P27
Description: Influenza A treatment drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.
Study: NCT04635462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise training
Description: Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise training
Description: Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
Study: NCT01872377

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost
Description: Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.
Study: NCT03072368

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photograph
Description: Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photograph
Description: Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photograph
Description: Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age
Study: NCT01756573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamthsone
Study: NCT03072368

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photograph
Description: Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age
Study: NCT00002590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study: NCT01756573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamthsone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine